Diffusion of surgical innovation among patients with kidney cancer by Miller, David C. et al.
Diffusion of Surgical Innovation Among Patients
With Kidney Cancer
David C. Miller, MD, MPH1,2
Christopher S. Saigal, MD, MPH1,2,3
Mousumi Banerjee, PhD4,5
Jan Hanley, MS3
Mark S. Litwin, MD, MPH1,2,3,6
and the Urologic Diseases in
America Project
1 Department of Urology, David Geffen School of
Medicine, University of California, Los Angeles,
California.
2 Jonsson Comprehensive Cancer Center, Univer-
sity of California, Los Angeles, California.
3 RAND Corporation, Santa Monica, California.
4 Department of Biostatistics, University of Michi-
gan School of Public Health, Michigan.
5 University of Michigan Comprehensive Cancer
Center.
6 Department of Health Services, School of Public
Health, University of California, Los Angeles, California.
BACKGROUND. Despite their potential benefits to patients with kidney cancer, the
adoption of partial nephrectomy and laparoscopy has been gradual and asym-
metric. To clarify whether this trend reflects differences in kidney cancer patients
or differences in surgeon practice styles, the authors compared the magnitude of
surgeon-attributable variance in the use of partial nephrectomy and laparoscopic
radical nephrectomy with that attributable to patient and tumor characteristics.
METHODS. By using linked Surveillance, Epidemiology, and End Results-Medicare
data, the authors identified a cohort of 5483 Medicare beneficiaries who under-
went surgery for kidney cancer between 1997 and 2002. Two primary outcomes
were defined: 1) the use of partial nephrectomy and (2) the use of laparoscopy
among patients undergoing radical nephrectomy. By using multilevel models,
surgeon- and patient-level contributions to observed variations in the use of par-
tial nephrectomy and laparoscopic radical nephrectomy were estimated.
RESULTS. Of the 5483 cases identified, 611 (11.1%) underwent partial nephrec-
tomy (43 performed laparoscopically), and 4872 (88.9%) underwent radical ne-
phrectomy (515 performed laparoscopically). After adjusting for patient
demographics, comorbidity, tumor size, and surgeon volume, the surgeon-attrib-
utable variance was 18.1% for partial nephrectomy and 37.4% for laparoscopy.
For both outcomes, the percentage of total variance attributable to surgeon fac-
tors was consistently higher than that attributable to patient characteristics.
CONCLUSIONS. For many patients with kidney cancer, the surgery provided
depends more on their surgeon’s practice style than on the characteristics of the
patient and his or her disease. Consequently, dismantling barriers to surgeon
adoption of partial nephrectomy and laparoscopy is an important step toward
improving the quality of care for patients with early-stage kidney cancer. Cancer
2008;112:1708–17.  2008 American Cancer Society.
KEYWORDS: kidney cancer, renal cell carcinoma, surgery, partial nephrectomy,
laparoscopy, technology adoption, practice patterns.
O pen radical nephrectomy is the traditional gold standard fortreating patients with organ-confined or locally advanced renal
cell carcinoma.1 During the last 2 decades, however, the concurrent
introduction of nephron-sparing (ie, partial nephrectomy) and
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minimally invasive (ie, renal laparoscopy) alternatives
to open radical excision have modified therapeutic
options appreciably.2–6
Easier convalescence7–10 and equivalent cancer
control10 have established laparoscopy as an alterna-
tive standard of care for most patients who undergo
radical nephrectomy.1,2,4,11,12 In synchronicity with
the gradual dissemination of laparoscopic radical ne-
phrectomy,2,4 multiple investigators reported that, for
selected patients with smaller renal tumors, partial
nephrectomy yields oncologic outcomes that are
indistinguishable from the outcomes achieved by
radical excision.13–15 Partial nephrectomy also pre-
serves long-term renal function16,17 while reducing
over-treatment of patients with benign18 or clinically
indolent19 tumors.
Despite these potential benefits to patients,
population-based data suggest that the adoption of
partial nephrectomy and laparoscopy has been grad-
ual and concentrated among select hospitals.4,12
Consequently, open radical nephrectomy remains the
predominant surgical therapy for Americans with
kidney cancer.3,4,12 Few data are available to clarify
whether current practice patterns for partial ne-
phrectomy and renal laparoscopy reflect differences
in kidney cancer patients or differences in the prac-
tice styles of their surgeons.
We hypothesized that surgeon-level factors influ-
ence the use of nephron-sparing and/or minimally
invasive surgery more than a patient’s demographic
or disease-related characteristics. We evaluated this
hypothesis by using multilevel analyses to estimate
the proportion of surgeon- and patient-attributable
variance in the use of partial nephrectomy and
laparoscopy while simultaneously accounting for
clustering of patients with kidney cancer within a
surgeons’ practice.20,21 By clarifying the relative con-
tribution of surgeon factors and patient factors, we
may be able to use these data to inform efforts to
accelerate the adoption of partial nephrectomy and
laparoscopy. Such adoption, in turn, could yield




We used linked data from the National Cancer Insti-
tute’s Surveillance, Epidemiology, and End Results
(SEER) Program and the Centers for Medicare and
Medicaid Services (CMS) to identify and characterize
a population-based cohort of older patients (aged
66 years) with incident kidney cancer diagnosed
from 1997 through 2002. SEER is a population-based
cancer registry that collects data regarding incidence,
treatment, and mortality. The demographic composi-
tion, cancer incidence, and mortality trends in the
SEER registries are representative of the entire United
States population.22
From 1997 through 1999, 11 SEER-affiliated
registries (San Francisco, San Jose, Los Angeles, Con-
necticut, Detroit, Hawaii, Iowa, New Mexico, Seattle,
Utah, and Atlanta) provided incident cases for link-
age with healthcare claims covered by the CMS. In
2000, the SEER-Medicare dataset was expanded to
include cases from the Greater California, Louisiana,
New Jersey, and Kentucky tumor registries. The Med-
icare Program provides primary health insurance for
97% of the United States population aged 65
years.23 Successful linkage with CMS claims is
achieved for >90% of Medicare patients whose can-
cer-specific data are tracked by SEER.23
Cohort Identification
We identified a preliminary cohort of 6515 Medicare
beneficiaries who were diagnosed between 1997 and
2002 with localized/regional, nonurothelial kidney
cancer. For each patient in the preliminary cohort,
we then searched both inpatient (Medicare Provider
Analysis and Review file; based on International Clas-
sification of Diseases, ninth revision, Clinical Modifi-
cation [ICD-9] codes) and physician claims (Carrier
Claims file; based on American Medical Association
Current Procedural Terminology [CPT] and ICD-9
codes) for kidney cancer-specific diagnosis and
procedure codes.
Of these beneficiaries, we excluded 1026 patients
who lacked claims denoting surgical treatment for
kidney cancer. We also excluded 3 patients (6 cases)
who had claims that suggested the presence of bilat-
eral tumors at diagnosis. This process yielded a final
analytic cohort of 5483 cases (84.2% of the prelimi-
nary cohort).
Surgical Procedures
Next, we defined and applied a claims-based algo-
rithm to determine the type of surgical therapy
received by each patient in the analytic cohort.
Recognizing that specific CPT codes for laparoscopic
radical nephrectomy (introduced in 2000) and
laparoscopic partial nephrectomy (introduced in
2002) did not exist during the earlier years of the
study, we identified laparoscopic cases using both
direct (CPT) and indirect (ICD-9 and CPT) laparo-
scopy codes.2,4,24 We also ascribed a laparoscopic
approach to patients with a live discharge and length
of stay 2 days after radical or partial nephrec-
tomy.2,4,24 By using this algorithm, we assigned each
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case to 1 of 4 mutually exclusive surgical categories:
1) open radical nephrectomy, 2) open partial ne-
phrectomy, 3) laparoscopic radical nephrectomy, and
4) laparoscopic partial nephrectomy.
We assessed the level of concordance between
our claims-based algorithm and the type of cancer-
directed surgery specified for each patient in the
SEER data file (Patient Entitlement and Diagnosis
Summary File) as validation. Although SEER does not
collect data regarding whether the surgical approach
was open or laparoscopic, we observed 97% agree-
ment for the assignment of partial versus radical ne-
phrectomy (j 5 0.83). In addition, we identified
relevant surgical pathology claims within 30 days of
the index admission for > 95% of the cases analyzed,
thus supporting the occurrence of cancer-directed
surgery.
Patient-level Covariates
We used SEER variables to ascertain demographic
and cancer-specific information (ie, age at surgery,
sex, race/ethnicity, marital status, SEER registry, year
of surgery, tumor size) for each patient in the analy-
tic cohort. We collapsed tumor size into 2 clinically
relevant groups based on a 4-cm threshold.14 We
assigned median Census-tract income and Census-
tract percentage of nonhigh school graduates as
patient-level measures of income and education,
respectively.25
We measured pre-existing comorbidity by using
a modification of the Charlson Index26 to identify
comorbid conditions (including diabetes, renal insuf-
ficiency, and cardiovascular disease) from inpatient
and physician claims that were submitted during the
12 months before the index admission for kidney
cancer surgery.27 We also noted the presence or ab-
sence of hypertension, urolithiasis, and/or renovas-
cular disease, given their relevance to surgical
decision-making among patients with kidney cancer.
Primary Surgeon
To identify the primary surgeon for each patient, we
used encrypted Unique Physician Identifier Num-
bers, which are submitted with Medicare physician
claims. By using claims from 1991 through 2002, we
also determined each surgeon’s average annual ne-
phrectomy (partial or radical) volume. We empirically
defined high-volume surgeons as those who per-
formed 3 annual cancer-related nephrectomies
among the SEER-Medicare population (83rd percen-
tile). This measure of case volume may not reflect
the total number of nephrectomies performed by a
provider: It fails to account for surgeries among
younger (non-Medicare-eligible) patients, Medicare
Health Maintenance Organization enrollees, and/or
fee-for-service Medicare participants who reside out-
side of the SEER registries.
Statistical Analysis
Before fitting multilevel models, we performed sev-
eral univariate analyses. We used chi-square tests to
evaluate the level of association between surgical
procedure and various patient-level covariates and to
assess the statistical significance of temporal surgical
trends.
For our multilevel analyses, we defined the fol-
lowing primary outcomes: 1) use of partial nephrec-
tomy and 2) use of laparoscopy among patients who
underwent radical nephrectomy. We hypothesized a
priori that kidney cancer patients are nested within
surgeons’ practices. Within this conceptual frame-
work, we fit multilevel models (also known as hierarch-
ical generalized linear models) to estimate surgeon-
and patient-level contributions to observed variations
in the use of partial nephrectomy and laparoscopy for
radical nephrectomy.20,21 Each model included a
unique surgeon identifier as a random-effects term.20,21
In a first set of models (ie, a model for partial
nephrectomy and a model for laparoscopic radical
nephrectomy), we estimated the surgeon-attributable
residual intraclass correlation coefficient (ICC). The
residual ICC estimates the proportion of the ‘‘left-
over’’ or unexplained variance in the use of partial
nephrectomy or laparoscopic radical nephrectomy
attributable to unmeasured surgeon factors (rather
than, for instance, unmeasured patient or hospital
factors) after accounting for the variance explained
by measured variables, such as patient demo-
graphics, prevalent comorbidity, tumor size, and sur-
geon case-volume classification. For the partial
nephrectomy outcome, we fit an additional model
based on a subsample of patients who were diag-
nosed in 2000 or later and had tumors that measured
4 cm (ie, the subsample of patients for whom par-
tial nephrectomy may have been most appropriate).
Next, we fit a series of models that estimated the
proportion of total variance (in the use of partial ne-
phrectomy and laparoscopy for radical nephrectomy)
that could be explained by surgeon factors and speci-
fic patient and tumor characteristics. For this step, the
initial model (known as the ‘‘unconditional model’’)
included only a surgeon-level random-effects term;
From the unconditional models, we calculated the sur-
geon-attributable variance without adjustment for case
volume, patient characteristics, or tumor characteris-
tics. Then, we estimated the proportion of total var-
iance explained by patient demographics, patient
comorbidity, tumor size, and surgeon volume classifi-
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cation by fitting separate models (for each outcome)
that included both a surgeon-level random-effects
term and only 1 of the following fixed-effect covariate
subsets: 1) surgeon case volume, 2) patient demo-
graphics, 3) medical comorbidity, and 4) tumor size.
For sensitivity analyses, we calculated the residual
ICC attributable to surgeons based on procedure
assignment without the length-of-stay assumption for
laparoscopy and based on a subsample of patients
(n 5 3989) in which only direct CPT and ICD-9 codes
were used to determine case assignment. We also
repeated the primary analyses after limiting our sample
to patients whose surgeons performed 3 nephrec-
tomies during the study period. We were unable to fit
models that also included surgeon-level covariates,
such as year of medical school graduation and practice
structure, because of computational limitations.
All statistical testing was 2-sided, completed by
using computerized software (SAS version 9.1; SAS
Institute, Cary, NC), and carried out at the 5% signifi-
cance level. We obtained approval for this study from




We identified a final analytic cohort comprising 5483
Medicare beneficiaries who underwent surgery for an
incident kidney cancer diagnosed between 1997 and
2002. Table 1 presents demographic and clinical
characteristics for patients in the analytic sample.
During the study interval, 611 patients (11.1%)
underwent partial nephrectomy (43 performed lapar-
oscopically), and 4872 patients (88.9%) underwent
radical nephrectomy (515 performed laparoscopi-
cally). We observed differences in treatment patterns
according to sex, marital status, SEER registry,
income, tumor size, and prevalent hypertension diag-
nosis (all P values <.05) (Table 1).
Surgical Practice Patterns
From 1997 through 2002, the proportion of patients
who underwent partial nephrectomy increased from
7.1% to 14.6% (P < .01); for patients who had tumors
that measured 4 cm, the proportion rose from 8.9%
to 23.5% (P < .01) (Fig. 1A). Among patients who had
tumors that measured 4 cm, laparoscopic radical
nephrectomy increased from 1.2% to 20.3%; for
patients with larger tumors, laparoscopic radical
nephrectomy increased from 0.8% to 16.2% (P
values < .01) (Fig. 1B).
In Table 2, we compare the use of surgical proce-
dures, stratified by comorbidity, from 1997 through
1999 and from 2000 through 2002. During both peri-
ods, laparoscopic radical nephrectomy decreased
among patients with greater comorbidity. The pro-
portion of partial nephrectomies (open or laparo-
scopic) remained similar across comorbidity strata.
Multilevel Models
We identified 1632 primary surgeons who performed
5025 kidney cancer surgeries (92% of all cases in the
analytic cohort) during the study interval. Among the
cases with identifiable primary surgeons, 364 differ-
ent surgeons performed 556 open or laparoscopic
partial nephrectomies (median, 1 procedure; range,
1–15 procedures). During the same interval, 4469
patients underwent open or laparoscopic radical ne-
phrectomy by 1570 different surgeons (median, 2
procedures; range, 1–27 procedures). Among the lat-
ter group, we distinguished 262 surgeons who per-
formed 495 laparoscopic procedures during the study
period (median, 1 procedure; range, 1–12 procedures).
In comparison, we identified 1485 different primary
surgeons for the 3974 open radical nephrectomies
(median, 2 procedures; range, 1–21 procedures).
We failed to identify a primary surgeon for 458
cases. On the basis of our empirical definition, we
classified 138 providers (8.4%) as high-volume sur-
geons; and 936 patients (18.6%) received treatment
by a high-volume surgeon.
In addition to the 458 cases for whom we could
not identify the primary surgeon, cases missing data
for 1 or more independent variables were also
excluded from the multivariate analyses. Thus, our
final partial nephrectomy and laparoscopy models
included 3995 cases (73% of the analytic sample) and
3565 cases (80% of radical nephrectomies in the ana-
lytic sample), respectively (Table 3).
Table 3 presents findings from our multilevel
analyses. For both the partial nephrectomy and
laparoscopy outcomes, we report the surgeon-attrib-
utable residual ICC, that is, the percentage of ‘‘left-
over’’ or unexplained variance in the use of the
procedure associated with the surgeon after adjusting
for available patient demographics, comorbidity, tu-
mor size, and surgeon volume. Table 3 also presents
the proportions of total variance in procedure use at-
tributable to unmeasured surgeon factors, surgeon
case volume, patient demographics, comorbidity, and
tumor size.
For our primary models, the proportions of var-
iance that were explained by measured variables
(patient demographics, comorbidity, tumor size, and
surgeon volume) were 22.5% and 23.2% for partial
nephrectomy and laparoscopy, respectively. With
respect to the remaining or ‘‘left-over’’ variance, the
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corresponding surgeon-attributable residual ICCs
were 18.1% and 37.4%, respectively. When we fit the
partial nephrectomy model for a subsample of
patients with small tumors (4 cm) diagnosed
between 2000 and 2002, the residual ICC for sur-
geons was 21.6% (Table 3).
With respect to partial nephrectomy, only the
proportion of total variance attributable to tumor
size (19.6%) exceeded that attributable to unmea-
sured surgeon factors (17.5%). Neither comorbidity
nor surgeon volume explained >5% of the total var-
iance in use of partial nephrectomy. The relative con-
tribution of surgeon factors and patient factors was
similar in analyses limited to patients with smaller
tumors (4 cm) diagnosed between 2000 and 2002
(Table 3).
For our laparoscopy outcome, the percentage of
total variance attributable to unmeasured surgeon
factors (37.5%) was substantially greater than that at-
tributable to surgeon case volume (13.9%), tumor
size (14.6%), comorbidity (13.4%), or patient demo-
graphics (20.7%) (Table 3). The partitioned variances
and residual ICC attributable to surgeons did not
change substantively in sensitivity analyses.
DISCUSSION
This study has 2 principal findings. First, and con-
sistent with prior population-based studies,2–4,12 the
use of both open partial nephrectomy and laparo-
scopic radical nephrectomy increased gradually
between 1997 and 2002; these trends notwithstand-
ing, through 2002, open radical nephrectomy
remained the predominant surgical therapy for older
Americans with kidney cancer. Second, for both pro-
TABLE 1




No. of patients (%)
LPN OPN LRN ORN
Total 43 (0.8) 568 (10.4) 515 (9.4) 4357 (79.5)
Age at surgery. y
66–69 12 (1.1) 142 (12.6) 92 (8.2) 880 (78.1)
70–74 11 (0.7) 183 (10.8) 143 (8.4) 1359 (80.1)
74–79 7 (0.5) 156 (10.6) 149 (10.1) 1164 (78.8)
80–84 9 (1) 68 (7.8) 95 (10.9) 698 (80.3)
85 <5 (1.3) 19 (6) 36 (11.4) 256 (81.3)
Sex*
Men 13 (0.6) 216 (9.5) 234 (10.3) 1801 (79.6)




39 (0.8) 468 (10.3) 441 (9.7) 3615 (79.2)
White, Hispanic <5 (0.3) 33 (9.8) 22 (6.6) 279 (83.3)
Black <5 (0.8) 46 (11.6) 32 (8.1) 315 (79.5)
Other or
unknown
<5 (0) 21 (11.1) 20 (10.6) 148 (78.3)
Marital status*,y
Married 31 (0.9) 362 (10.8) 312 (9.3) 2648 (79)
Not married 10 (0.5) 184 (9.6) 186 (9.7) 1539 (80.2)
SEER registry*
Atlanta <5 (1.8) 12 (7.1) 15 (8.8) 140 (82.4)
Connecticut <5 (0.6) 48 (9.6) 50 (10) 400 (79.8)
Detroit 6 (0.9) 82 (12.3) 57 (8.5) 522 (78.3)
Greater
California
<5 (0.5) 50 (8.5) 62 (10.5) 476 (80.5)
Hawaii <5 (0) <5 (4.7) <5 (4.7) 58 (90.6)
Iowa <5 (0.2) 48 (9) 25 (4.7) 460 (86.1)
Kentucky <5 (0.8) 34 (9.4) 42 (11.5) 285 (78.3)
Los Angeles 8 (1.5) 79 (14.4) 43 (7.8) 419 (76.3)
Louisiana 5 (1.5) 29 (9) 43 (13.4) 245 (76.1)
New Jersey 7 (1) 78 (10.8) 91 (12.5) 549 (75.7)
New Mexico <5 (0) 12 (7.1) 10 (6) 146 (86.9)
Rural Georgia <5 (0) <5 (5.9) <5 (17.7) 13 (76.5)
San Francisco <5 (0.5) 30 (15.4) 25 (12.8) 139 (71.3)
San Jose <5 (0) 15 (11) 7 (5.1) 115 (83.9)
Seattle <5 (0.6) 28 (8.4) 28 (8.4) 276 (82.6)
Utah <5 (0.7) 19 (13.1) 11 (7.6) 114 (78.6)
Median census tract income{,§
<$35,000 9 (0.7) 120 (9.3) 112 (8.7) 1050 (81.3)
$35,000–44,999 8 (0.6) 132 (10.4) 101 (7.9) 1033 (81.1)
$45,000–59,999 13 (0.9) 148 (10.2) 154 (10.7) 1128 (78.2)
$60,000 12 (0.9) 147 (11.3) 132 (10.2) 1005 (77.6)
Percentage of residents in Census tract with less than a high school educationk
>25 8 (0.7) 124 (10.5) 101 (8.6) 944 (80.2)
15.1–25 11 (0.9) 108 (8.9) 114 (9.4) 979 (80.8)
10–15 8 (0.8) 98 (9.9) 107 (10.9) 774 (78.4)
<10 12 (0.8) 175 (12.1) 148 (10.2) 1116 (76.9)
Tumor size, cm*,}
4 34 (1.5) 415 (17.7) 260 (11.1) 1631 (69.7)
>4 6 (0.2) 112 (3.8) 238 (8) 2604 (88)
Charlson Index score
0 22 (0.7) 337 (10.4) 319 (9.8) 2573 (79.1)
1 11 (0.8) 137 (10.2) 120 (9) 1074 (80)





No. of patients (%)
LPN OPN LRN ORN
Hypertension*
Yes 25 (0.9) 305 (11.5) 235 (8.8) 2092 (78.8)
No 18 (0.6) 263 (9.3) 280 (9.9) 2265 (80.2)
LPN indicates laparoscopic partial nephrectomy; OPN, open partial nephrectomy; LRN, laparoscopic
radical nephrectomy; ORN, open radical nephrectomy; SEER, Surveillance, Epidemiology, and End
Results Program.
* P <.05 (general chi-square test).
y Marital status was unknown for 211 patients.
{ Information on income was missing for 179 patients.
§ P <.05 (chi-square test for linear trend).
k Information on education was missing for 656 patients.
} Information on tumor size was missing for 183 patients.
1712 CANCER April 15, 2008 / Volume 112 / Number 8
FIGURE 1. (A) Distribution of surgical therapies for patients with tumors 4 cm (1997–2002). (B) Distribution of surgical therapies for patients with
tumors >4 cm (1997–2002).
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cedures, the proportion of total variance attributable
to surgeon factors exceeded that for almost all
patient and tumor characteristics, including tumor
size and comorbidity. The ensuing inference is that a
minority of elderly patients with kidney cancer
undergoes nephron-sparing or minimally invasive sur-
gery; moreover, surgeon-level determinants appear to
influence the likelihood of undergoing a partial
nephrectomy or a laparoscopic approach for radical
nephrectomy as much as or greater than a patient’s
tumor size, demographic characteristics, or general
medical health.
Our findings are consequential clinically insofar
as the benefits of partial nephrectomy16,28 and
laparoscopy7–9 support the application of 1 or both
of these techniques for a majority (rather than a mi-
nority) of patients with organ-confined renal tumors.
Evidence for the feasibility of this paradigm comes
from multiple contemporary case series in
which >50% of patients with tumors 4 cm under-
went a partial nephrectomy (or another kidney-
sparing technique); at these centers, most of the
patients who did not undergo kidney-sparing treat-
ment underwent laparoscopic radical nephrec-
tomy.5,6,29 The finding that, even in 2002, 2 of 3
Medicare beneficiaries with kidney cancer underwent
an open radical nephrectomy highlights an opportu-
nity for population-level improvements in the quality
of surgical care. In fact, it is elderly patients who may
benefit most from treatments that preserve renal func-
tion and/or ease postoperative convalescence.
Reducing clinical uncertainty is a necessary step
toward the goal of optimizing surgical practice pat-
terns. The debut of (and progressively broadening
indications for) partial nephrectomy and laparoscopy
fragmented professional consensus regarding the
standard therapy for patients with small, organ-
confined renal masses.11,30–32 Emblematic of this
concern is the finding that both open partial ne-
phrectomy and laparoscopic radical nephrectomy are
used most frequently among patients with small
tumors (4 cm) and little comorbidity. Likewise, the
persistently high proportion of surgeon-attributable
variance among patients with tumors 4 cm (ie,
those for whom partial nephrectomy may have been
most feasible) further underscores the extant uncer-
tainty regarding the relative benefits of kidney-spar-
ing and minimally invasive surgery.
In the setting of such uncertainty, individual sur-
geons may have developed distinctive approaches to
the treatment of otherwise similar patients with kid-
ney cancer (so-called surgical signatures).33,34 The
finding that the percentage of provider-attributable
TABLE 2
Surgical Therapies for Early-stage Kidney Cancer by Year of Diagnosis
and Charlson Index Strata*
CI
No. of patients (%)
1997–1999 2000–2002y
LPN OPN LRN ORN LPN OPN LRN ORN
0 <5 78 (8) 27 (2.8) 871 (89.2) 22 (1) 259 (11.4) 292 (12.8) 1702 (74.8)
1 <5 23 (6.5) 8 (2.3) 320 (90.9) 10 (1) 114 (11.5) 112 (11.3) 754 (76.2)
2 <5 17 (7.5) 4 (1.8) 206 (90.7) 10 (1.5) 77 (11.6) 72 (10.9) 504 (76)
CI indicates Charlson Index; LPN, laparoscopic partial nephrectomy; OPN, open partial nephrec-
tomy; LRN, laparoscopic radical nephrectomy; ORN, open radical nephrectomy.
* P > .20 (Cochran-Mantel-Haenszel chi-square test).
y Includes a small number of patients who were diagnosed in late 2002 who did not undergo surgery
until 2003.
TABLE 3
Surgeon and Patient Contributions to Variance in the Use of Partial











No. of patients 3995 3565 1364











Patient demographics 7.4 20.7 9.4
Comorbidity 4.7 13.4 6.7
Tumor size 19.6 14.6 —
* The multilevel model for use of laparoscopy was based on the subsample of patients who under-
went radical nephrectomy.
y This row presents the percentage of variance attributable to the surgeon after adjusting for patient
and tumor characteristics as well as surgeon nephrectomy case volume (the residual intraclass corre-
lation coefficient). The denominator for calculation of this proportion includes the residual variance
attributable to the surgeon random effect (after adjustment for patient demographics, comorbidity,
tumor size, and surgeon case volume) and the variance attributable to unmeasured patient or tumor
variables plus error.
{ The denominator for the calculation of partitioned-variance proportions is the total. The total var-
iance includes 3 components: 1) the variance attributable to the surgeon (after adjustment for the
corresponding fixed-effect covariate[s] in a given model); 2) the variance attributable to the corre-
sponding measured covariate(s) (ie, the fixed effects); and 3) the variance attributable to unmeasured
patient or tumor variables plus error. The partitioned variance attributable to the surgeon is esti-
mated using an ‘‘unconditional’’ model, which includes a surgeon-level random-effects term as the
only independent variable; accordingly, the denominator for calculation of this percentage includes
only 2 components: 1) the variance attributable to the surgeon unadjusted for any other covariates
and 2) the variance attributable to unmeasured patient or tumor variables plus error.
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variance in our analysis was higher than that
reported in other clinical studies35,36 using multilevel
modeling techniques supports the validity of this hy-
pothesis and highlights the need for additional stu-
dies and/or consensus-based clinical guidelines that
clarify optimal surgical treatment algorithms for
patients with kidney cancer (including the appropriate
integration of ablative therapies37 and surveillance
protocols38).
Although these data are consistent with the
proposition that a surgeon’s kidney cancer case vol-
ume is associated with the use of partial nephrec-
tomy and laparoscopy,4,12 the relatively greater
percentage of variance attributable to nonvolume-
related surgeon factors underscores the potential le-
verage of other provider-adoption barriers related to
technical complexity,39,40 practice setting,41,42 and
informational resources.42 For instance, during the
years that we studied, few practicing urologists
received formal training in laparoscopy; moreover,
relatively small kidney cancer caseloads further
deterred uptake of this technique.40,43 In view of
these barriers, several mentored and simulator-based
training programs consequently emerged to facilitate
skill transfer from experienced to laparoscopy-naive
urologists.44–46
The high percentage of provider-attributable var-
iance also may reflect unmeasured differences in
practice setting (and consequent access to informa-
tion) among surgeons in our sample. That is, most
providers make conclusive decisions about innova-
tions based on interactions with local peer adopters
rather than on scientific research or mass-media
channels.40,42 For the use of partial nephrectomy and
laparoscopy, therefore, the high proportion of sur-
geon-attributable variance may signify an asym-
metric distribution of local surgical colleagues who
assess the procedure, refine its application, and then
use informal communication channels to facilitate
propagation among other potential adopters in their
community.5,40,42 Recognizing that social connections
and local informational resources facilitate the diffu-
sion of new surgical therapies,39,40,42,47 we see inno-
vative collaborations between urologists—informed
by established practice-based surgical research mod-
els48–51—as representing a potential mechanism for
accelerating the adoption of partial nephrectomy and
renal laparoscopy.
Alternatively, it is possible that payer-initiated
referral policies could emerge that circumvent adop-
tion barriers by promoting the concentration of sur-
gical care among providers with established
proficiency in the spectrum of surgical treatment
options for patients with kidney cancer (the
‘‘centers-of-excellence’’ model).48 This potential pol-
icy lever has several limitations, including its reliance
on imperfect methods for identifying ‘‘excellent’’
providers,48 its indifference to patient preferences
for where they receive care,52 its potential to yield
delays in care as a result of saturation of designated
providers,53 its failure to address the obstacles
encountered by surgeons endeavoring to adopt bene-
ficial innovations,40,51 and its assumption that varia-
tions in convalescence and morbidity (as opposed to
mortality) sufficiently motivate a policy-based inter-
vention. Ultimately, the development of specific
interventions to increase the use of partial nephrec-
tomy and laparoscopy will be informed by future stu-
dies that further characterize surgeon-level (eg,
attitudes, practice structure and setting) and hospi-
tal-level (eg, technology, ancillary staff) determinants
of adoption as well as patient preferences.
Our study had several limitations. First, current
SEER-Medicare data reflect the earlier years after
urologists’ acceptance of partial nephrectomy and
laparoscopy; more recent data may reveal expanded
use of these techniques with a smaller percentage of
provider-attributable variance.54 There is evidence,
however, that the use of these techniques remained
stable in 2003 and 2004.2,55 Second, the generalizabil-
ity of our results was restricted by a sample that was
limited to patients aged 66 years who had tradi-
tional fee-for-service Medicare coverage. Nonethe-
less, linked SEER-Medicare data provided a unique
opportunity to evaluate variations in kidney cancer
care in the context of clinically important case-mix
variables, including tumor size and medical comor-
bidity. Third, we could not explicitly measure all clin-
ical variables that were relevant to surgical decision
making. Consequently, we were unable to distinguish
reliably which patients had recognized contraindica-
tions to nephron-sparing and/or minimally invasive
surgery. Fourth, we defined high-volume surgeons
empirically rather than based on existing criteria;
alternative volume thresholds may have changed the
proportion of variance explained by surgeon case
volume.
Fifth, although we posit that the expanded use of
partial nephrectomy and laparoscopy is a desirable
objective, we also recognize that clarifying the opti-
mal use of these procedures will require a better
understanding of patient preferences. This is particu-
larly relevant given the potentially dissimilar nonon-
cologic outcomes (eg, intensity of convalescence,
short-term complications) after different surgical
therapies. Sixth, our algorithm for assigning surgical
procedure necessarily assigns a single treatment for
the small number of cases with a discrepancy in sur-
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gical procedure classification based on inpatient
claims versus physician claims. Thus, our primary
outcome is susceptible to some degree of misclassifi-
cation; however, sensitivity analyses confirmed our
principal findings. Finally, our findings are subject to
potential selection bias based on observed differences
(eg, sex, race, income) between patients who were
excluded and patients who were included in our multi-
variable models. The observed differences, however,
were small in magnitude and lacked clinical signifi-
cance. In addition, excluded and included patients did
not differ in tumor size, education, or marital status,
and the 2 groups were similar with respect to the distri-
bution of surgical therapies.
This report describes patterns of surgical care for
elderly Americans with kidney cancer. Specifically,
despite their potential advantages relative to open
radical nephrectomy, partial nephrectomy and
laparoscopy are used relatively infrequently in this
population; moreover, much of the variance in their
use is attributable to surgeon-specific factors rather
than patient- or tumor-specific factors. Thus, for
many older patients with kidney cancer, the surgery
provided may depend more on their surgeon’s prac-
tice style than on the characteristics of the patient
and his or her disease. Consequently, the timely dis-
mantling of residual barriers to surgeons’ adoption of
partial nephrectomy and laparoscopy is an important
step toward improving the quality of care provided
to patients with kidney cancer.
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